Minimum Inhibitory Concentration (MIC) Testing

Advanced Minimum Inhibitory Concentration (MIC) Testing Services – From Reference Broth Microdilution to Mechanistic Resistance Profiling and Breakpoint Validation

The precise and reproducible determination of the minimum inhibitory concentration (MIC) is the cornerstone of antimicrobial susceptibility testing, providing the most reliable quantitative measure of the activity of an antimicrobial agent against a specific bacterial or fungal isolate. The MIC – the lowest concentration of an antimicrobial that visibly inhibits the growth of the organism after overnight incubation – is essential not only for guiding clinical therapy and detecting emerging resistance, but also for the development and registration of new antibiotics, Antifungal agents, and combination therapies. Regulatory and clinical standards, including CLSI M07, ISO 20776‑1, and EUCAST guidelines, require that MICs be determined using validated, reference‑quality methods, with stringent quality control and appropriate statistical analysis. However, a reliable MIC determination is not a trivial task; it is critically dependent on the choice of method (broth microdilution, agar dilution, or gradient strip), the preparation of the inoculum, the composition of the medium, the incubation conditions, and, most importantly, the accurate reading of the endpoint. A poorly performed assay can lead to misclassification of susceptibility, under‑ or overestimation of potency, and misleading conclusions, which can have severe clinical, regulatory, and commercial consequences. Our ISO/IEC 17025‑accredited and GMP‑compliant laboratory offers a fully integrated MIC testing platform, encompassing the full range of methods – from the gold‑standard broth microdilution (BMD) and agar dilution to the gradient strip (E‑test) and automated microdilution systems – and we can adapt to any organism, any antimicrobial, and any regulatory requirement. We deliver quantitative, traceable MIC values, with full statistical interpretation, determination of the modal MIC, and, where requested, the characterisation of the resistance mechanism (e.g., ESBL, carbapenemase, or efflux). Our expert microbiologists provide comprehensive interpretation, enabling you to make informed decisions, to validate new agents, and to meet the most stringent quality and regulatory standards.

1. The Scientific and Regulatory Rationale for Precise MIC Determination

The MIC is a fundamental pharmacological parameter that defines the intrinsic activity of an antimicrobial. It is used for multiple critical purposes: (a) to guide the selection of optimal antimicrobial therapy for individual patients (by comparing the MIC to the achievable serum/tissue concentrations); (b) to detect and monitor the emergence of resistance (by tracking MIC creep or the emergence of resistant subpopulations); (c) to support the development and registration of new antibiotics by establishing the susceptibility profile against a large panel of clinical isolates; (d) to determine the breakpoints used by regulatory agencies; (e) to evaluate the activity of new combination therapies (by determining the fractional inhibitory concentration index, FICI); and (f) to characterise the pharmacodynamic profile (by determining the MIC distribution and the mutant prevention concentration, MPC). The choice of the method – whether reference broth microdilution (the “gold standard”), agar dilution, the gradient strip, or automated instruments – must be justified based on the organism, the antimicrobial, the laboratory’s infrastructure, and the required precision. All methods must be validated to demonstrate that they are accurate, reproducible, and free from interference. Our service begins with a thorough consultation to define the optimal MIC determination strategy, ensuring that the data are scientifically robust, and that the method is fully compliant with the relevant CLSI, EUCAST, or ISO standards.

2. Our Comprehensive MIC Testing Platform – Reference and Automated Methods

We maintain a complete suite of validated MIC methods, all performed in a dedicated microbiology facility with stringent quality controls, and using certified reference strains (e.g., E. coli ATCC 25922, S. aureus ATCC 29213, P. aeruginosa ATCC 27853, and C. albicans ATCC 90028) for daily quality assurance. Our portfolio includes:

2.1 Reference Broth Microdilution (BMD) – The Gold Standard (CLSI M07, ISO 20776‑1)
We perform the broth microdilution method in 96‑well microtiter plates, using cation‑adjusted Mueller‑Hinton broth (CAMHB) for bacteria, or RPMI‑1640 for fungi. A standardised inoculum (typically 5×10⁵ CFU/mL) is added to wells containing a two‑fold dilution series of the antimicrobial. After incubation (16‑24 hours for most bacteria, 24‑48 hours for fungi), the MIC is read as the lowest concentration that inhibits visible growth. We include all the necessary controls: the growth control, the Sterility control, and the positive and negative QC strain controls. The BMD method is the reference against which all other methods are calibrated and is essential for the validation of new antimicrobials and for the confirmation of resistant isolates.

2.2 Agar Dilution – For Fastidious Organisms and for Testing Multiple Strains
For organisms that are difficult to grow in broth (e.g., Streptococcus spp., anaerobes, Haemophilus), we use the agar dilution method (CLSI M11 for anaerobes). The antimicrobial is incorporated into Mueller‑Hinton agar (supplemented with appropriate growth factors), and the organism is spot‑inoculated. The MIC is determined as the lowest concentration that inhibits visible growth on the agar surface.

2.3 Gradient Strip (E‑test) – A Convenient and Precise Alternative
We use the gradient strip (E‑test) for the rapid and accurate determination of the MIC of individual antimicrobials. This method employs a plastic strip impregnated with a continuous concentration gradient of the antibiotic, which is placed onto an agar plate inoculated with the test organism. After incubation, an elliptical inhibition zone is formed, and the MIC is read directly from the scale on the strip. We provide the MIC value in μg/mL, and we also verify the result against the reference BMD method if required.

2.4 Automated Microdilution Systems – VITEK, Phoenix, and MicroScan
We employ fully automated systems (e.g., VITEK 2, BD Phoenix, and MicroScan WalkAway) for the high‑throughput and rapid (4‑6 hours) determination of MICs. These systems use a combination of broth microdilution and colorimetric/fluorometric detection to generate precise MICs for a comprehensive panel of antimicrobials. We perform daily quality control and we verify any unexpected or critical results by the reference BMD method.

2.5 MIC for Anaerobes – Specialised Methods and Media
For anaerobic bacteria (e.g., Bacteroides spp., Clostridium spp.), we use the agar dilution method with Brucella agar supplemented with hemin, vitamin K1, and 5% sheep blood, as recommended by CLSI M11. The plates are incubated in an anaerobic chamber for 48 hours, and the MIC is determined as described.

2.6 MIC for Fungi – Yeasts and Moulds (CLSI M27, M38)
We determine the MIC for yeasts (Candida spp., Cryptococcus spp.) using the broth microdilution method with RPMI‑1640 medium and a spectrophotometrically adjusted inoculum (0.5‑2.5×10³ CFU/mL). For moulds (Aspergillus spp., Mucorales), we use the broth microdilution method with RPMI‑1640 and a larger inoculum (0.4‑5×10⁴ CFU/mL). We follow the CLSI M27‑Ed4 (yeasts) and M38‑Ed3 (moulds) guidelines, and we report the MIC with the standard interpretation.

2.7 MIC for Mycobacteria – Broth Microdilution (CLSI M24, M62)
We specialise in the MIC determination for Mycobacterium tuberculosis and non‑tuberculous mycobacteria (NTM) using the broth microdilution method in Middlebrook 7H9 broth (or on solid Middlebrook 7H10/7H11), following the CLSI M24 (NTM) and M62 (MTB) guidelines. We use the correct inoculum and the appropriate incubation conditions (5‑7 days for M. tuberculosis, 10‑14 days for NTM).

3. Advanced Capabilities – Mechanistic Deep‑Dive, Custom Panels, and Breakpoint Studies

For clients requiring a deeper understanding of the antimicrobial activity or a high‑level validation of their product, we offer a suite of customised, research‑grade services that go beyond routine MIC determination:

3.1 MIC Distribution and Epidemiological Cut‑off (ECOFF) Determination
We can determine the MIC distribution for a large panel of clinical isolates to establish the wild‑type distribution and to identify non‑wild‑type (NWT) isolates. This is essential for establishing the ECOFF, which is a key component for the validation of new antimicrobial breakpoints.

3.2 Mutant Prevention Concentration (MPC) – Preventing the Emergence of Resistance
We determine the mutant prevention concentration – the concentration required to prevent the growth of the first‑step resistant mutants – using the method of agar dilution with a high inoculum (10¹⁰ CFU/mL). The MPC provides valuable pharmacodynamic data for dosing strategies designed to minimise the emergence of resistance.

3.3 Time‑Kill Kinetics and Synergy/Additivity Studies – Checkerboard and Fractional Inhibitory Concentration Index (FICI)
We perform time‑kill studies at multiple concentrations (e.g., 0.5×, 1×, 2×, 4× MIC) to evaluate the rate and extent of bacterial killing. We also perform synergy studies using the checkerboard method, which involves a two‑dimensional dilution of two agents, and we calculate the fractional inhibitory concentration index (FICI) to classify the interaction as synergistic (FICI ≤ 0.5), additive (FICI 0.5‑1), or antagonistic (FICI > 4).

3.4 Minimum Bactericidal Concentration (MBC) and Minimum Fungicidal Concentration (MFC)
We determine the minimum bactericidal (or fungicidal) concentration by sub‑culturing wells from the MIC plate that show no visible growth. The MBC/MFC is the lowest concentration that kills ≥ 99.9% of the initial inoculum. This is an important parameter for cidal agents.

3.5 Resistance Mechanism Elucidation – Whole‑Genome Sequencing and PCR
We combine MIC data with molecular analysis to identify the specific resistance mechanisms. This includes PCR for the detection of resistance genes (e.g., bla_KPC, mecA, vanA) and whole‑genome sequencing (WGS) to identify mutations in target genes (e.g., gyrA for fluoroquinolone resistance, rpoB for rifampicin) and to detect the presence of resistance plasmids. We provide a comprehensive report linking the genotype to the phenotype.

3.6 MIC Validation and Regulatory Submission Support
We provide full method validation for your MIC assay, including the demonstration of: (a) accuracy (against the reference BMD method); (b) precision (intra‑assay, inter‑assay, and inter‑operator); (c) reproducibility (using multiple media batches and instrument settings); and (d) robustness to variations in inoculum and incubation conditions. The validation report is structured to meet the requirements of the FDA, EMA, or other regulatory agencies.

4. Data Integrity, Standardisation, and Comprehensive Reporting

All assays are conducted under a strict quality management system that includes the use of certified reference strains, routine daily controls (including the appropriate QC strains), and participation in proficiency testing schemes (e.g., the UK NEQAS, CAP, or the CLSI organized PT). Our reports provide:

• Full method description – detailing the organism, the antimicrobial, the test method, the media, the inoculum, and the incubation conditions.
• Detailed results – including the MIC value in μg/mL, the modal MIC (if multiple replicates are performed), and a clear interpretation (S, I, R) according to the most current CLSI or EUCAST breakpoints.
• Quality control data – the results of the concurrent QC strains, confirming the validity of the test run.
• Molecular resistance data (if requested) – the presence/absence of specific resistance genes and the interpretation.
• Graphical outputs – including the MIC distribution or dose‑response curve, if required.
• Interpretative comments – including notes on the likely resistance mechanism, the clinical significance (based on PK/PD targets), and any recommendations for further testing (e.g., MBC, synergy).

Our reports are authored by senior clinical microbiologists and infectious disease pharmacologists who provide not just raw data, but contextual insights to guide your clinical, research, or regulatory decisions.

Turnaround times: 48‑72 hours for standard MIC determination (BMD, gradient strip), 24‑48 hours for automated systems, and 3‑5 days for mycobacterial and fungal MICs. Extended time is required for synergy, MPC, or WGS studies.

5. Our Unmatched Expertise – Why Choose Our Laboratory for MIC Testing

We are one of the few laboratories that hold ISO/IEC 17025 accreditation and GMP compliance for the full spectrum of MIC methods, including BMD, agar dilution, gradient strip, and automated systems, for bacteria, fungi, and mycobacteria. Our integrated infrastructure combines a reference microbiology laboratory, a molecular diagnostics unit, and a bioinformatics core – enabling cross‑verification of results and a comprehensive understanding of both the phenotype and the genotype. Our team comprises PhD‑level clinical microbiologists, pharmacologists, and bioinformaticians with extensive experience in MIC method development, validation, and regulatory submissions, and we have a proven track record of supporting pharmaceutical development, clinical microbiology, and public health surveillance.

We offer unparalleled flexibility: we accept a wide range of clinical and environmental isolates – from common pathogens (E. coli, S. aureus, Klebsiella, Pseudomonas, Candida) to fastidious organisms (Streptococcus, Haemophilus, Neisseria, anaerobes, and mycobacteria) – and we provide customised antimicrobial panels for novel agents and specific resistance surveillance. Our secure online portal enables real‑time tracking, access to raw data, and downloadable certificates of analysis.

Our modular pricing ensures cost‑effectiveness: you select the level of analysis – from a simple MIC determination to a full synergy and mechanism study – with discounts for routine monitoring programmes and bulk submissions. We also provide training, method transfer, and technical consultancy to help you build or strengthen your internal MIC testing capabilities.

With a proven history of serving over 100 clients in the clinical, veterinary, and pharmaceutical sectors, we have enabled our partners to improve patient outcomes, combat antimicrobial resistance, and accelerate drug development. We invite you to leverage our expertise for your minimum inhibitory concentration testing needs.

Contact our technical experts today to discuss your test organisms, antimicrobial panels, and specific requirements. We will design a tailored testing plan and provide a detailed proposal within one business day.